Glenmark Pharmaceuticals Limited (Glenmark), an innovation-driven global pharmaceutical company, has become the first to launch Thiazolidinedione Lobeglitazone (Lobeglitazone) in India for the treatment of type 2 diabetes in adults. Marketed under the brand name LOBG; it contains Lobeglitazone (0.5 mg) and to be taken once daily under prescription to improve glycemic control in adult diabetic patients.
Glenmark earlier received approval from the Indian drug regulator, Drug Controller General of India, for manufacturing and marketing Lobeglitazone based on a randomized, double-blind Phase 3 clinical trial conducted on adult Type 2 diabetic patients, aged 18 years and older.
The results of this trial have shown a faster and improved glycemic control with Lobeglitazone. On the occasion of the launch, Alok Malik, EVP & Business Head – India Formulations, Glenmark Pharmaceuticals, said, “we are proud to introduce LOBG; an innovative and affordable drug, which will help in tackling insulin resistance among adult patients suffering from uncontrolled Type 2 diabetes in the country.”
